OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $213.34 million. The enterprise value is $229.14 million.
| Market Cap | 213.34M |
| Enterprise Value | 229.14M |
Important Dates
The next estimated earnings date is Wednesday, March 11, 2026, before market open.
| Earnings Date | Mar 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.64 million shares outstanding. The number of shares has increased by 4.08% in one year.
| Current Share Class | 18.64M |
| Shares Outstanding | 18.64M |
| Shares Change (YoY) | +4.08% |
| Shares Change (QoQ) | +2.34% |
| Owned by Insiders (%) | 15.31% |
| Owned by Institutions (%) | 66.67% |
| Float | 14.28M |
Valuation Ratios
The trailing PE ratio is 6,226.88 and the forward PE ratio is 16.21.
| PE Ratio | 6,226.88 |
| Forward PE | 16.21 |
| PS Ratio | 1.97 |
| Forward PS | 1.89 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 24.57 |
| P/FCF Ratio | 18.71 |
| P/OCF Ratio | 18.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.68, with an EV/FCF ratio of 19.48.
| EV / Earnings | 6,739.47 |
| EV / Sales | 2.09 |
| EV / EBITDA | 20.68 |
| EV / EBIT | 33.91 |
| EV / FCF | 19.48 |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.05 |
| Quick Ratio | 2.90 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 2.53 |
| Debt / FCF | 2.43 |
| Interest Coverage | 1.20 |
Financial Efficiency
Return on equity (ROE) is 0.03% and return on invested capital (ROIC) is 0.10%.
| Return on Equity (ROE) | 0.03% |
| Return on Assets (ROA) | 2.52% |
| Return on Invested Capital (ROIC) | 0.10% |
| Return on Capital Employed (ROCE) | 4.45% |
| Weighted Average Cost of Capital (WACC) | 9.10% |
| Revenue Per Employee | $848,884 |
| Profits Per Employee | $264 |
| Employee Count | 129 |
| Asset Turnover | 0.65 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OptimizeRx has paid $1.65 million in taxes.
| Income Tax | 1.65M |
| Effective Tax Rate | 97.98% |
Stock Price Statistics
The stock price has increased by +112.71% in the last 52 weeks. The beta is 1.09, so OptimizeRx's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +112.71% |
| 50-Day Moving Average | 13.46 |
| 200-Day Moving Average | 14.49 |
| Relative Strength Index (RSI) | 36.35 |
| Average Volume (20 Days) | 226,207 |
Short Selling Information
The latest short interest is 1.66 million, so 8.89% of the outstanding shares have been sold short.
| Short Interest | 1.66M |
| Short Previous Month | 1.69M |
| Short % of Shares Out | 8.89% |
| Short % of Float | 11.60% |
| Short Ratio (days to cover) | 6.49 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $109.51 million and earned $34,000 in profits. Earnings per share was $0.00.
| Revenue | 109.51M |
| Gross Profit | 71.52M |
| Operating Income | 6.76M |
| Pretax Income | 1.69M |
| Net Income | 34,000 |
| EBITDA | 11.08M |
| EBIT | 6.76M |
| Earnings Per Share (EPS) | $0.00 |
Balance Sheet
The company has $19.52 million in cash and $28.61 million in debt, with a net cash position of -$9.09 million or -$0.49 per share.
| Cash & Cash Equivalents | 19.52M |
| Total Debt | 28.61M |
| Net Cash | -9.09M |
| Net Cash Per Share | -$0.49 |
| Equity (Book Value) | 122.26M |
| Book Value Per Share | 6.58 |
| Working Capital | 37.85M |
Cash Flow
In the last 12 months, operating cash flow was $11.83 million and capital expenditures -$64,000, giving a free cash flow of $11.76 million.
| Operating Cash Flow | 11.83M |
| Capital Expenditures | -64,000 |
| Free Cash Flow | 11.76M |
| FCF Per Share | $0.63 |
Margins
Gross margin is 65.31%, with operating and profit margins of 6.17% and 0.03%.
| Gross Margin | 65.31% |
| Operating Margin | 6.17% |
| Pretax Margin | 1.54% |
| Profit Margin | 0.03% |
| EBITDA Margin | 10.12% |
| EBIT Margin | 6.17% |
| FCF Margin | 10.74% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.08% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.02% |
| FCF Yield | 5.34% |
Analyst Forecast
The average price target for OptimizeRx is $19.67, which is 71.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.67 |
| Price Target Difference | 71.87% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 2.58 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.58 |
| Piotroski F-Score | 7 |